CRO INC Research posted another quarter of double-digit revenue growth, lifting its 2015 guidance for the second time to account for a jump in new business.
Contract drugmaker Patheon is getting out of agrochemicals and selling off a manufacturing plant, narrowing its focus on pharmaceutical development as it plots an IPO.
Covance, acquired by LabCorp for about $6 billion earlier this year, has picked former head of R&D Deborah Keller to take the reins as CEO Joseph Herring retires.
Charles River Laboratories saw its sales dip in the second quarter, but the early-stage specialist is counting on some recent acquisitions to spur growth for the full year.
PRA Health Sciences is ticking up its full-year expectations after another quarter of revenue growth, counting on a steady stream of new business.
Icon is again reducing its revenue expectations for 2015 but increasing its profit guidance, counting on a big quarter of business wins to balance some sluggish backlog conversion.
Quintiles is going back to its earlier optimism for 2015, scaling up its previously reduced growth projections after posting a strong sales quarter.
Contract drug developer Avista Pharma Solutions bought the manufacturing, development and animal health services business of rival Scynexis, building up its capacity to take a larger share of an expanding market.
Covance, recently acquired by testing giant LabCorp, has opened a new, expanded clinical research unit in Texas, pairing space for trials alongside a planned patient-service center operated by its parent company.
PRA Health Sciences, looking to find the next generation of clinical researchers, is dialing up its recruitment pitch in hopes of meeting the escalating demand for CRO-run trials around the world.
The recently merged Huntingdon Life Sciences and Harlan Laboratories have convinced their investors to commit up to $125 million in equity financing, lining up the cash they'll need to move forward as a joint entity.
Indian drugmaker Biocon is on the road to taking its in-house CRO public, and the company's founder said she's considering making the company an entirely independent operation.
Contract drugmaker AMRI paid $174 million for a Spanish manufacturing operation, part of the company's long-term plan to dial up its focus on production.
Contract drug developer Almac has opened a new shop in Singapore, a facility that will serve as the company's Asian headquarters as it plots more investments in the region.
CROs Icon and Covance signed a pair of separate partnerships in the world of cancer diagnostics, each betting that new technologies in oncology testing will increase global demand.
Contract drug developer Aptuit has bolstered its in-house production capabilities and can now churn out doses for Phase III trials, a move the company says was motivated by client demand.
Patient recruitment specialist Synexus has opened up new outposts across Eastern Europe, following through on its promise to expand around the globe after changing hands for $128 million.
CRO Frontage Laboratories has acquired a 45% stake in New Jersey's BDM Consulting, a biometrics-focused company looking to expand the market for its data services.
Chinese CRO giant WuXi PharmaTech is looking to expand its investment portfolio, planning to debut a $250 million new fund that will back startups in the U.S. and China.
Swedish contractor Recipharm has deepened its ties with partner Pharmanest, taking up a 25% stake in the biotech as the two collaborate on a pain drug.